Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NYU Langone Health

Go Back to All Clinical Trials

Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Relapsed/refractory Precursor B-cell Or T-cell Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma
Age: Between 1 years - 30 years
Gender: Male or Female

Other Inclusion Criteria:

1. Documented Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma 2. Second or greater relapse or refractory to 2 prior induction regimens for B-ALL 3. First or greater relapse or refractory to 1 prior induction/consolidation regimen for T-ALL

You may not be eligible for this study if the following are true:

1. Received an allogeneic hematopoietic transplant within 3 months 2. Active acute graft-versus-host disease 3. Received immunosuppression post hematopoietic transplant within 1 month of study entry